Comparative assessment of gadoxetate disodium, manganese dipyridoxal diphosphate, and superparamagnetic iron oxide for enhancement of the liver in dogs.
Khangure
M S
MS
Department of Radiology, Royal Perth Hospital, Western Australia.
Hua
J
J
D000818:Animals; D003287:Contrast Media / Q000633:toxicity; D004285:Dogs; D004492:Edetic Acid / Q000031:analogs & derivatives* / Q000633:toxicity; D005260:Female; D052203:Ferrosoferric Oxide; D019786:Gadolinium DTPA; D007089:Image Enhancement; D007501:Iron / Q000633:toxicity; D007668:Kidney / Q000187:drug effects / Q000473:pathology; D008099:Liver / Q000187:drug effects / Q000473:pathology*; D008279:Magnetic Resonance Imaging; D008297:Male; D009942:Organometallic Compounds / Q000633:toxicity; D010087:Oxides / Q000633:toxicity; D004369:Pentetic Acid / Q000031:analogs & derivatives* / Q000633:toxicity; D011732:Pyridoxal Phosphate / Q000031:analogs & derivatives* / Q000633:toxicity; D012737:Sex Factors
D003287:Contrast Media; D009942:Organometallic Compounds; D010087:Oxides; C073590:gadolinium ethoxybenzyl DTPA; D011732:Pyridoxal Phosphate; D004369:Pentetic Acid; D004492:Edetic Acid; D007501:Iron; D019786:Gadolinium DTPA; C060076:N,N'-bis(pyridoxal-5-phosphate)ethylenediamine-N,N'-diacetic acid; D052203:Ferrosoferric Oxide